AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

A Brit woman was given a shocking diagnosis of stage 4 breast cancer after she said her tumour was repeatedly dismissed as ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

Lea first spotted a small lump on her right breast but was reassured her 'lumpy boobs' were just due to hormones ...

A woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as 'lumpy boobs' for two years. Lea ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

AstraZeneca is jointly developing and commercializing ENHERTU, which is the drug being evaluated in the DESTINY-Endometrial01 phase 3 trial, with Daiichi Sankyo under a global collaboration.

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair ...

(Alliance News) - AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus ...